SCYNEXIS, Inc.

288 articles with SCYNEXIS, Inc.

• SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections

  12/7/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the SCYNEXIS’s New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infections

• SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

  11/24/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference.

• SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update

  11/6/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to potentially overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2020 and provided an update on recent clinical and corporate developments.

• SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections

  10/21/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-stage, novel broad-spectrum antifungal, ibrexafungerp, at IDWeek 2020.

• SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

  10/14/2020

  NDA s ubmission is supported by positive data from two Phase 3 studies ( VANISH Program ) in women with vulvovaginal candidiasis (VVC) As a qualified infectious disease product (QIDP) , ibrexafungerp is expected to receive a 6-month priority review following NDA acceptance

• SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference

  10/12/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two posters at the Nurse Practitioners in Women Health’s (NPWH) 23rd Annual Premier Women's Healthcare Virtual Conference to be held from October 15 – October 17, 2020. The posters will highlight the robust Phase 3 data on ibrexafungerp, a novel

• SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar

  9/10/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright’s 22 nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim’s anti

• SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis

  8/13/2020

  Two oral presentations by VVC experts on ibrexafungerp, one in-vitro activity study and one on VANISH-303 study   SCYNEXIS to sponsor symposium: “Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis” JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two oral

• SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update

  8/10/2020

  In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains on track for Q4 2020. In July, SCYNEXIS held an investor event with two key opinion leaders (KOLs) to discuss patient perspectives, unmet needs and treatment options in VVC, as well as the related commercial opportunity. This event fo

• SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis

  7/29/2020

  Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.

• SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

  7/22/2020

  Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infections

• SCYNEXIS Announces One-for-Ten Reverse Stock Split

  7/16/2020

  SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 12:01 a.m. ET on July 17, 2020. SCYNEXIS common stock will begin trading on a split-adjusted basis commencing upon market open on July 17, 202

• SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections

  7/9/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a key opinion leader (KOL) discussion via webcast entitled “An Uncomfortable Discussion: The Immediate Need in Treating Women with Vaginal Yeast Infections” on Tuesday, July 14, 2020 at 10am Eastern Time.

• SCYNEXIS to Present at the BIO Digital International Convention 2020

  6/8/2020

  Company presentation will highlight progress towards transitioning to a fully integrated commercial stage company with an initial focus on vaginal yeast infection

• 

  BioSpace Movers & Shakers, June 5

  6/5/2020

  Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.

• SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

  6/2/2020

  Appointment of seasoned women’s health marketing executive is a key step in the transition to a fully-integrated drug development and commercial company with initial focus on vaginal yeast infection

• 

  Biopharma Update on the Novel Coronavirus: May 27

  5/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.

• SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

  5/11/2020

  In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is on track for the second half of 2020   Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; top-line results and supplemental NDA submission anticipated in the s

• SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

  5/6/2020

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the publication of six abstracts in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book, now available online.

• SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

  4/28/2020

  SCYNEXIS, Inc. announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel discussion on fungal pathogens and the emerging treatment landscape at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020.